#Setidegrasib (ASP3082) takes a protein degradation approach. It is designed to selectively bind KRAS G12D and recruit an E3 ligase, leading to ubiquitination and subsequent proteasomal degradation of the mutant protein.
October 21, 2026 at 9:11 AM
#Setidegrasib (ASP3082) takes a protein degradation approach. It is designed to selectively bind KRAS G12D and recruit an E3 ligase, leading to ubiquitination and subsequent proteasomal degradation of the mutant protein.
Read the full article here:
biotechstockdaily.com/uncategorize...
biotechstockdaily.com/uncategorize...
Astellas Brings 21 Abstracts to ESMO 2026, Results Still Under Wraps - BioTech Stocks Daily
Astellas previews 21 ESMO 2026 abstracts on Padcev, Vyloy, Xtandi and setidegrasib. No results disclosed yet; here is what is already known
biotechstockdaily.com
October 12, 2026 at 2:42 AM
Read the full article here:
biotechstockdaily.com/uncategorize...
biotechstockdaily.com/uncategorize...
【KRAS G12D分解薬setidegrasib、肺がんで第3相開始】
アステラス製薬。KRAS G12Dタンパク質を分解する薬。白金化学療法と免疫チェックポイント阻害薬のあとの進行・転移NSCLCで、ドセタキセルと比べる。主要評価はPFSとOS。約356例。6カ月以内では膵管腺がんに続く2件目の第3相。開始の発表であり、成績ではない。
アステラス製薬、KRAS G12D変異NSCLCで新規分解薬setidegrasibの第3相治験開始──ドセタキセルと比較、6カ月で2件目の第3相移行
stellanews.life/technology/1...
アステラス製薬。KRAS G12Dタンパク質を分解する薬。白金化学療法と免疫チェックポイント阻害薬のあとの進行・転移NSCLCで、ドセタキセルと比べる。主要評価はPFSとOS。約356例。6カ月以内では膵管腺がんに続く2件目の第3相。開始の発表であり、成績ではない。
アステラス製薬、KRAS G12D変異NSCLCで新規分解薬setidegrasibの第3相治験開始──ドセタキセルと比較、6カ月で2件目の第3相移行
stellanews.life/technology/1...
アステラス製薬、KRAS G12D変異NSCLCで新規分解薬setidegrasibの第3相治験開始──ドセタキセルと比較、6カ月で2件目の第3相移行
アステラス製薬は、KRAS G12D変異を有する既治療の進行非小細胞肺がん患者を対象に、新規標的タンパク質分解薬setidegrasibとドセタキセルを比較する第3相試験で最初の患者への投与を開始したと発表した。
stellanews.life
September 28, 2026 at 4:12 AM
【KRAS G12D分解薬setidegrasib、肺がんで第3相開始】
アステラス製薬。KRAS G12Dタンパク質を分解する薬。白金化学療法と免疫チェックポイント阻害薬のあとの進行・転移NSCLCで、ドセタキセルと比べる。主要評価はPFSとOS。約356例。6カ月以内では膵管腺がんに続く2件目の第3相。開始の発表であり、成績ではない。
アステラス製薬、KRAS G12D変異NSCLCで新規分解薬setidegrasibの第3相治験開始──ドセタキセルと比較、6カ月で2件目の第3相移行
stellanews.life/technology/1...
アステラス製薬。KRAS G12Dタンパク質を分解する薬。白金化学療法と免疫チェックポイント阻害薬のあとの進行・転移NSCLCで、ドセタキセルと比べる。主要評価はPFSとOS。約356例。6カ月以内では膵管腺がんに続く2件目の第3相。開始の発表であり、成績ではない。
アステラス製薬、KRAS G12D変異NSCLCで新規分解薬setidegrasibの第3相治験開始──ドセタキセルと比較、6カ月で2件目の第3相移行
stellanews.life/technology/1...
https://trecome.info/articles/ff82be57-79e3-4cd4-91ad-36f7cfe09667
【新着記事】
アステラスのsetidegrasib、非小細胞肺がんP3開始／ロシュ、取締役にウェバー氏推薦へ など｜製薬業界きょうのニュースまとめ読み（2026年9月24日）
【新着記事】
アステラスのsetidegrasib、非小細胞肺がんP3開始／ロシュ、取締役にウェバー氏推薦へ など｜製薬業界きょうのニュースまとめ読み（2026年9月24日）
September 25, 2026 at 6:02 AM
https://trecome.info/articles/ff82be57-79e3-4cd4-91ad-36f7cfe09667
【新着記事】
アステラスのsetidegrasib、非小細胞肺がんP3開始／ロシュ、取締役にウェバー氏推薦へ など｜製薬業界きょうのニュースまとめ読み（2026年9月24日）
【新着記事】
アステラスのsetidegrasib、非小細胞肺がんP3開始／ロシュ、取締役にウェバー氏推薦へ など｜製薬業界きょうのニュースまとめ読み（2026年9月24日）
Astellas Initiates Phase 3 Study of Setidegrasib for Advanced Lung Cancer Patients#Japan#Tokyo#Astellas_Pharma#KRAS_G12D#setidegrasib
Astellas Initiates Phase 3 Study of Setidegrasib for Advanced Lung Cancer Patients
Astellas has commenced a Phase 3 clinical trial of setidegrasib targeting advanced lung cancer with KRAS G12D mutation, exploring new treatment options for patients.
third-news.com
September 23, 2026 at 11:34 PM
Astellas Initiates Phase 3 Study of Setidegrasib for Advanced Lung Cancer Patients#Japan#Tokyo#Astellas_Pharma#KRAS_G12D#setidegrasib
A new drug called setidegrasib doesn’t just block the KRAS cancer protein; it destroys it. First-in-human trial shows tumor shrinkage in lung & pancreatic cancers. Published today in the NEJM. www.uclahealth.org/news/release... #KRAS #LungCancer #PancreaticCancer #TCSC
Targeted therapy drug shows early promise against KRAS-driven lung and pancreatic cancers
The therapy shrank tumors in some patients and delayed disease progression, marking a potential step forward for cancers with few targeted treatment options.
www.uclahealth.org
April 28, 2026 at 8:00 AM
A new drug called setidegrasib doesn’t just block the KRAS cancer protein; it destroys it. First-in-human trial shows tumor shrinkage in lung & pancreatic cancers. Published today in the NEJM. www.uclahealth.org/news/release... #KRAS #LungCancer #PancreaticCancer #TCSC
Setidegrasib (KRAS G12D degrader) for NSCLC and PDAC ,Phase I trial
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer | NEJM
The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patient...
www.nejm.org
March 26, 2026 at 4:13 AM
Setidegrasib (KRAS G12D degrader) for NSCLC and PDAC ,Phase I trial
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
A first-in-class #KRAS G12D-targeted protein degrader active in #lung and #pancreatic #cancer patients: pubmed.ncbi.nlm.nih.gov/41879829/
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer - PubMed
Setidegrasib was associated with antitumor activity and a low incidence of treatment discontinuation due to adverse events in patients with previously treated advanced <i>KRAS</i> p.G12D-mutated NSCLC or pancreatic ductal adenocarcinoma. (Funded by Astellas Pharma; ClinicalTrials.gov number, NCT0538 …
pubmed.ncbi.nlm.nih.gov
March 26, 2026 at 1:05 PM
A first-in-class #KRAS G12D-targeted protein degrader active in #lung and #pancreatic #cancer patients: pubmed.ncbi.nlm.nih.gov/41879829/
"In March, Park & colleagues reportd results of the 1st KRAS degrader 2B tested in humans. The drug, called setidegrasib & made by Astellas Pharma in Tokyo, shrank tumours in more than 1/3 of participants w/a form of #lungcancer & nearly 1/4 of those w/a form of #pancreaticcancer." #CanSky #FuckYeah
New drugs take aim at one of cancer’s deadliest mutations
Mutations in the KRAS protein were once deemed ‘undruggable’. Today, various approaches are in the pipeline.
www.nature.com
April 8, 2026 at 4:41 PM
"In March, Park & colleagues reportd results of the 1st KRAS degrader 2B tested in humans. The drug, called setidegrasib & made by Astellas Pharma in Tokyo, shrank tumours in more than 1/3 of participants w/a form of #lungcancer & nearly 1/4 of those w/a form of #pancreaticcancer." #CanSky #FuckYeah
MSK gastrointestinal medical oncologist Dr. Wungki Park led a global phase 1 clinical trial of #setidegrasib, which shows early promise in aggressive #lung and #pancreatic cancers.
Learn more about this research: https://bit.ly/3Nsijjm
Learn more about this research: https://bit.ly/3Nsijjm
March 27, 2026 at 8:00 PM
MSK gastrointestinal medical oncologist Dr. Wungki Park led a global phase 1 clinical trial of #setidegrasib, which shows early promise in aggressive #lung and #pancreatic cancers.
Learn more about this research: https://bit.ly/3Nsijjm
Learn more about this research: https://bit.ly/3Nsijjm
🆙 #ELCC26 @myesmo.bsky.social
🔥Proffered Paper session 1
☑️Setidegrasib in KRAS G12D
🎯ORR 35.6%, mPFS 8.3m
🎙️Dr. Philippe CASSIER
🎙️Chair: @solangepeters.bsky.social
📍NCT05382559
@oncoalert.bsky.social LARVOL #LCSM
🔥Proffered Paper session 1
☑️Setidegrasib in KRAS G12D
🎯ORR 35.6%, mPFS 8.3m
🎙️Dr. Philippe CASSIER
🎙️Chair: @solangepeters.bsky.social
📍NCT05382559
@oncoalert.bsky.social LARVOL #LCSM
March 19, 2026 at 2:06 PM
🆙 #ELCC26 @myesmo.bsky.social
🔥Proffered Paper session 1
☑️Setidegrasib in KRAS G12D
🎯ORR 35.6%, mPFS 8.3m
🎙️Dr. Philippe CASSIER
🎙️Chair: @solangepeters.bsky.social
📍NCT05382559
@oncoalert.bsky.social LARVOL #LCSM
🔥Proffered Paper session 1
☑️Setidegrasib in KRAS G12D
🎯ORR 35.6%, mPFS 8.3m
🎙️Dr. Philippe CASSIER
🎙️Chair: @solangepeters.bsky.social
📍NCT05382559
@oncoalert.bsky.social LARVOL #LCSM
🔜 #ELCC26 @myesmo.bsky.social
🔥Proffered Paper session 1
☑️Setidegrasib in KRAS G12D
☑️TOP study: Osimertinib +/- Chemo in EGFRm + TP53m
☑️iza-bren + serplulimab in SCLC
☑️Obrixtamig + ezabenlimab in DLL3+ SCLC
🎙️Chair: @solangepeters.bsky.social
@oncoalert.bsky.social LARVOL #LCSM
🔥Proffered Paper session 1
☑️Setidegrasib in KRAS G12D
☑️TOP study: Osimertinib +/- Chemo in EGFRm + TP53m
☑️iza-bren + serplulimab in SCLC
☑️Obrixtamig + ezabenlimab in DLL3+ SCLC
🎙️Chair: @solangepeters.bsky.social
@oncoalert.bsky.social LARVOL #LCSM
March 16, 2026 at 2:30 PM
🔜 #ELCC26 @myesmo.bsky.social
🔥Proffered Paper session 1
☑️Setidegrasib in KRAS G12D
☑️TOP study: Osimertinib +/- Chemo in EGFRm + TP53m
☑️iza-bren + serplulimab in SCLC
☑️Obrixtamig + ezabenlimab in DLL3+ SCLC
🎙️Chair: @solangepeters.bsky.social
@oncoalert.bsky.social LARVOL #LCSM
🔥Proffered Paper session 1
☑️Setidegrasib in KRAS G12D
☑️TOP study: Osimertinib +/- Chemo in EGFRm + TP53m
☑️iza-bren + serplulimab in SCLC
☑️Obrixtamig + ezabenlimab in DLL3+ SCLC
🎙️Chair: @solangepeters.bsky.social
@oncoalert.bsky.social LARVOL #LCSM
Feed: "Medical News, Health News Latest, Medical News Today - Medical Dialogues |"
By: Dr. Shravani Dali on Wednesday, April 1, 2026
By: Dr. Shravani Dali on Wednesday, April 1, 2026
Setidegrasib Shows Promise for KRAS G12D–Mutated lung and pancreatic Cancers: NEJM
Setidegrasib, an emerging targeted therapy, has shown promising efficacy in a phase I trial involving patients with previously treated advanced pancreatic ductal adenocarcinoma (PDAC) and non-small...
medicaldialogues.in
April 1, 2026 at 4:03 PM
Feed: "Medical News, Health News Latest, Medical News Today - Medical Dialogues |"
By: Dr. Shravani Dali on Wednesday, April 1, 2026
By: Dr. Shravani Dali on Wednesday, April 1, 2026
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Saturday, March 28, 2026
Published on Saturday, March 28, 2026
Setidegrasib in KRAS G12D-Mutant NSCLC and Pancreatic Cancer: A New Frontier Opens in Precision Oncology
Setidegrasib showed promising activity in KRAS G12D-mutant NSCLC and pancreatic cancer, supporting protein degradation as a new precision oncology strategy.
oncodaily.com
March 29, 2026 at 3:36 AM
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Saturday, March 28, 2026
Published on Saturday, March 28, 2026
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Wednesday, March 25, 2026
Published on Wednesday, March 25, 2026
Setidegrasib Shows Promising Activity in KRAS G12D-Mutant NSCLC
Setidegrasib shows promising efficacy and safety in KRAS G12D-Mutant NSCLC, offering a potential new targeted therapy option for this unmet need.
oncodaily.com
March 26, 2026 at 3:10 AM
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Wednesday, March 25, 2026
Published on Wednesday, March 25, 2026
Immunogenicity and Safety of a Yellow Fever Vaccine nej.md/4sq5Lay
Setidegrasib in Advanced NSCLC and Pancreatic Cancer nej.md/3O0pWNY
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Setidegrasib in Advanced NSCLC and Pancreatic Cancer nej.md/3O0pWNY
Subscribe to NEJM for the latest medical research: nej.md/subscribe
April 9, 2026 at 11:58 AM
Immunogenicity and Safety of a Yellow Fever Vaccine nej.md/4sq5Lay
Setidegrasib in Advanced NSCLC and Pancreatic Cancer nej.md/3O0pWNY
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Setidegrasib in Advanced NSCLC and Pancreatic Cancer nej.md/3O0pWNY
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Presented at #ELCC26:
In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. Full trial results: nej.md/3O0pWNY
@myesmo.bsky.social
In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. Full trial results: nej.md/3O0pWNY
@myesmo.bsky.social
March 25, 2026 at 3:50 PM
Presented at #ELCC26:
In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. Full trial results: nej.md/3O0pWNY
@myesmo.bsky.social
In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. Full trial results: nej.md/3O0pWNY
@myesmo.bsky.social
An investigational therapy targeting KRAS G12D showed early signs of tumor shrinkage and delayed progression in advanced lung and pancreatic cancers, with manageable side effects in initial testing. doi.org/hbz946
Experimental KRAS G12D drug slows cancer growth, shrinks tumors in early test
A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug designed to eliminate a key cancer-driving protein called KRAS G12D, shows encouraging early activity in patients with advanced lung and pancreatic cancers.
medicalxpress.com
May 2, 2026 at 2:00 PM
An investigational therapy targeting KRAS G12D showed early signs of tumor shrinkage and delayed progression in advanced lung and pancreatic cancers, with manageable side effects in initial testing. doi.org/hbz946
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer | NEJM
The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patient...
www.nejm.org
March 26, 2026 at 12:31 AM
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment#United_States#Florida_Cancer_Specialists#Fort_Myers#KRAS_G12D#setidegrasib
Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment
A Phase 1 clinical trial concluded that setidegrasib targets KRAS G12D mutations effectively, showing promise for lung and pancreatic cancer patients.
third-news.com
April 2, 2026 at 3:35 PM
Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment#United_States#Florida_Cancer_Specialists#Fort_Myers#KRAS_G12D#setidegrasib